Pharmaceutical CDMO - Market: Size, Share, Growth, Analysis, Key Players, Revenue, Growth | Valuates Reports

Pharmaceutical CDMO - Market Size
The global market for Pharmaceutical CDMO was estimated to be worth US$ 128270 million in 2023 and is forecast to a readjusted size of US$ 217220 million by 2030 with a CAGR of 7.7% during the forecast period 2024-2030

View sample report
https://reports.valuates.com/request/sample/QYRE-Auto-39T13723/Global_Pharmaceutical_CDMO_Market_Research_Report_2023

Pharmaceutical CDMO - Market
A CDMO is a company dedicated to providing drug development and manufacturing services for the pharmaceutical and biotechnology industries. CDMO activities can broadly be divided into four fields: product development, manufacture of active pharmaceutical ingredients (API), manufacture of finished dosage forms (FDF) and pharma packaging.
Contract Pharmaceutical Manufacturing is part of CDMO, refers to accept commissioned from pharmaceutical companies, provide the service about API production, FDF production, packaging.
Pharmaceutical companies are likely to outsource a wide range of manufacturing related activities including - primary and secondary packaging, formulation, active ingredient manufacturing, labeling, clinical supplies, sterilization, manufacturing of chemical intermediates, etc. CDMOs support pharmaceutical companies at all stages of the process of making medicines: by providing services in the research and development stages, by offering support in manufacturing, and by providing formulating and finishing processes.
The key service providers of the Pharmaceutical CDMO in the world are Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics and Siegfried, among which the market share of the top three service providers exceeds 10%, and Lonza is the largest service provider. The services provided by global pharmaceutical CDMO are mainly distributed in North America, Europe and China, among which the top three regions account for nearly 60% of the market share, and North America is currently the largest service provider. In terms of its service type, the growth rate of FDF CDMO is relatively fast. At present, the market share of API CDMO is the highest, more than 40%, followed by FDF CDMO, packaging CDMO and clinical CDMO. In terms of its application, pharmaceutical company are the largest application field, with a market share of more than 60%, followed by biotechnology company.

Get regional report
https://reports.valuates.com/request/regional/QYRE-Auto-39T13723/Global_Pharmaceutical_CDMO_Market_Research_Report_2023

Segment by Type:
• API CDMO
• FDF CDMO
• Packaging CDMO
• Clinical CDMO

Segment by Application
• Pharmaceutical Company
• Biotechnology Company
• Other

By Company
Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics, Siegfried, FUJIFILM Diosynth Biotechnologies, Asymchem, Pfizer CentreOne, Delpharm, Recipharm, AGC Pharma Chemicals, Boehringer Ingelheim, Vetter, Curia, Aenova, Porton, Piramal, Strides Pharma, NextPharma, Famar, Jubilant, Alcami, Euroapi, Eurofins, Avid Bioservices, BioVectra, CPL

View full report
https://reports.valuates.com/market-reports/QYRE-Auto-39T13723/global-pharmaceutical-cdmo

Valuates,
4th Floor,
Balaraj's Arcade,
Whitefield Main road,
Bangalore 560066,

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.

This release was published on openPR.